SCHEMBL19851224

SCHEMBL19851224

CNCc1ccc(NC(=S)NC)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.62
SMN1; SMN2 Q16637 4/20 0.55
MAPT P10636 4/20 0.55
GAA P10253 2/20 0.55
CYP1A2 P05177 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
HPGD P15428 1/20 0.55
L3MBTL1 Q9Y468 2/20 0.51
POLB P06746 1/20 0.50
RAB9A P51151 1/20 0.50
LMNA P02545 2/20 0.47
ALOX12 P18054 1/20 0.47
HTT P42858 1/20 0.47
MAOA P21397 2/20 0.46
MAOB P27338 2/20 0.46
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
ATM Q13315 1/20 0.45
LSS P48449 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19851219 0.87 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2MAPTGAACYP1A2
SCHEMBL19851240 0.85 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2MAPTGAACYP1A2
SCHEMBL17469336 0.82 ALDH1A1 (0.64) ALDH1A1SMN1; SMN2MAPTGAACYP1A2
SCHEMBL19997538 0.82 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2MAPTGAACYP1A2
SCHEMBL8867893 0.79 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2MAPTGAACYP1A2
SCHEMBL8867884 0.78 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2MAPTGAACYP1A2
SCHEMBL3976381 0.78 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2MAPTGAACYP1A2
SCHEMBL20808597 0.77 LOXL2 (0.42) ALDH1A1SMN1; SMN2MAPTGAAHPGD
SCHEMBL13693551 0.75 MAPT (0.62) ALDH1A1SMN1; SMN2MAPTGAACYP1A2
SCHEMBL11550071 0.75 MAPT (0.67) ALDH1A1SMN1; SMN2MAPTGAACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10753942-B2 Methods to detect remnant cancer cells INDICATOR SYSTEMS INTERNATIONAL, INC. (US) 2020-08-25 US disclosed
US-20200150127-A1 BIOPSY METHODS AND DEVICES INDICATOR SYSTEMS INTERNATIONAL, INC. 2020-05-14 US disclosed
US-20190107543-A1 METHODS TO DETECT REMNANT CANCER CELLS INDICATOR SYSTEMS INTERNATIONAL, INC. (US) 2019-04-11 US disclosed
WO-2018026538-A1 NOVEL SCAFFOLDS FOR INTRACELLULAR COMPOUND DELIVERY FOR THE DETECTION OF CANCER CELLS ISI Life Sciences Inc. (US) 2018-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200150127-A1 BIOPSY METHODS AND DEVICES MKI67, RNASE1, CD63 ALDH1A1 1461/4885SMN1; SMN2 917/4885MAPT 4516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.